Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669062 | 0.90 | ENPP2 (0.42) | ENPP2KDM4EALDH1A1MGLLOPRL1 | |
| SCHEMBL29954777 | 0.86 | ENPP2 (0.45) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL3784993 | 0.82 | ENPP2 (0.48) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL27054112 | 0.79 | TAAR1 (0.44) | PRMT5WDR77CTSDBACE1 | |
| SCHEMBL14685875 | 0.79 | TAAR1 (0.44) | PRMT5WDR77CTSDBACE1 | |
| SCHEMBL3783525 | 0.79 | HDAC4 (0.51) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL3786808 | 0.79 | HDAC4 (0.47) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL3784746 | 0.77 | KMO (0.53) | ENPP2KDM4EALDH1A1MGLLHDAC4 | |
| SCHEMBL23715083 | 0.76 | KDM1A (0.44) | HTR6PRMT5WDR77OPRL1HDAC4 | |
| SCHEMBL17247328 | 0.76 | PRMT5 (0.41) | KDM4EALDH1A1HTR6PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| EP-3433254-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433255-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162572-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB3 | ENPP2 446/4885KDM4E 3706/4885ALDH1A1 1222/4885 |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, GP6 | ENPP2 454/4885KDM4E 3675/4885ALDH1A1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.